ClariVest Asset Management LLC Acquires Shares of 74,700 BioCryst Pharmaceuticals, Inc. (BCRX)

ClariVest Asset Management LLC acquired a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 74,700 shares of the biotechnology company’s stock, valued at approximately $392,000. ClariVest Asset Management LLC owned approximately 0.08% of BioCryst Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of BCRX. RA Capital Management LLC increased its stake in shares of BioCryst Pharmaceuticals by 47.9% during the 2nd quarter. RA Capital Management LLC now owns 5,162,242 shares of the biotechnology company’s stock worth $28,702,000 after purchasing an additional 1,672,447 shares in the last quarter. FMR LLC increased its stake in shares of BioCryst Pharmaceuticals by 114.5% during the 2nd quarter. FMR LLC now owns 3,124,676 shares of the biotechnology company’s stock worth $17,373,000 after purchasing an additional 1,667,791 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of BioCryst Pharmaceuticals by 49.1% during the 1st quarter. Vanguard Group Inc. now owns 5,011,763 shares of the biotechnology company’s stock worth $42,098,000 after purchasing an additional 1,651,292 shares in the last quarter. State Street Corp boosted its position in BioCryst Pharmaceuticals by 72.0% during the second quarter. State Street Corp now owns 3,909,013 shares of the biotechnology company’s stock worth $21,736,000 after acquiring an additional 1,636,909 shares during the last quarter. Finally, Jennison Associates LLC boosted its position in BioCryst Pharmaceuticals by 47.8% during the third quarter. Jennison Associates LLC now owns 3,076,461 shares of the biotechnology company’s stock worth $16,121,000 after acquiring an additional 995,643 shares during the last quarter. 72.06% of the stock is owned by institutional investors and hedge funds.

In related news, Director Fred E. Cohen sold 54,250 shares of BioCryst Pharmaceuticals stock in a transaction on Monday, September 18th. The shares were sold at an average price of $5.42, for a total transaction of $294,035.00. Following the transaction, the director now owns 173,660 shares in the company, valued at approximately $941,237.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO William P. Sheridan sold 64,310 shares of BioCryst Pharmaceuticals stock in a transaction on Monday, November 13th. The shares were sold at an average price of $4.72, for a total transaction of $303,543.20. The disclosure for this sale can be found here. Insiders own 5.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://sportsperspectives.com/2017/11/23/clarivest-asset-management-llc-acquires-shares-of-74700-biocryst-pharmaceuticals-inc-bcrx.html.

BioCryst Pharmaceuticals, Inc. (NASDAQ BCRX) opened at $4.64 on Thursday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $3.95 and a 1-year high of $9.25. The company has a current ratio of 2.53, a quick ratio of 2.53 and a debt-to-equity ratio of 0.21.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.18). The business had revenue of $8.76 million for the quarter, compared to analyst estimates of $5.05 million. BioCryst Pharmaceuticals had a negative net margin of 167.58% and a negative return on equity of 123.16%. The business’s quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.16) EPS. equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.72 EPS for the current year.

A number of brokerages recently issued reports on BCRX. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Wednesday, November 8th. Royal Bank Of Canada began coverage on shares of BioCryst Pharmaceuticals in a research report on Thursday, September 14th. They set a “sector perform” rating and a $6.00 target price on the stock. J P Morgan Chase & Co raised their target price on shares of BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 6th. Jefferies Group LLC upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the stock from $5.00 to $7.00 in a research report on Wednesday, September 6th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $15.00 target price (up previously from $13.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 5th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $9.13.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply